HeadInvest LLC’s Editas Medicine EDIT Stock Holding History

HeadInvest LLC’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-132	Closed	-$942	–	352
2023 Q3	$942	Buy	+132	New	+$1.13K	﹤0.01%	712

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HeadInvest LLC's EDIT Position: Q4 2023 in Review

HeadInvest LLC sold out of Editas Medicine (EDIT) in Q4 2023, closing a stake of 132 shares — an estimated $942 sold.

HeadInvest LLC first reported a position in EDIT in Q3 2023 and held it in 1 quarter. The position peaked at $942 in Q3 2023. 225 funds tracked by Wall St. Rank hold EDIT as of Q4 2023.

HeadInvest LLC reported no remaining Editas Medicine position as of Q4 2023 after selling out during the quarter.
HeadInvest LLC sold 132 Editas Medicine shares in Q4 2023, an estimated $942.
HeadInvest LLC first reported a position in Editas Medicine in Q3 2023 and held it in 1 quarter.
HeadInvest LLC's Editas Medicine position peaked at $942 in Q3 2023.
225 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2023.

Based on HeadInvest LLC's 13F filing for Q4 2023, filed 12 Feb 2024.